Show simple item record

dc.creatorOrtiz-Guerrero, Gloria 
dc.creatorAmador-Muñoz, Diana 
dc.creatorCalderon-Ospina, Carlos-Alberto 
dc.creatorLópez-Fuentes, Daniel 
dc.creatorNava Mesa, Mauricio Orlando 
dc.date.accessioned2019-01-17T19:15:08Z
dc.date.available2019-01-17T19:15:08Z
dc.date.created2018
dc.date.issued2018 
dc.identifier.issnISSN 2090-5904
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/18882
dc.descriptionAlzheimer's disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged =65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (Aß) and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aß levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective. © 2018 Gloria Ortiz-Guerrero et al.
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.relation.ispartofNeural Plasticity, ISSN:2090-5904, Vol. 2018 (2018)
dc.relation.urihttps://www.hindawi.com/journals/np/2018/5257285/
dc.subjectDemencia
dc.subject.lembInhibidores de la bomba de protones
dc.subject.lembDemencia
dc.titleProton pump inhibitors and dementia : Physiopathological mechanisms and clinical consequences
dc.typearticle
dc.subject.keywordProton Pump Inhibitors
dc.subject.keywordDementia
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.type.spaArtículo
dc.rights.accesoAbierto (Texto Completo)
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.source.bibliographicCitationPrince, M., Wimo, A., Guerchet, M., Claire Ali, G., Wu, Y.-T., Prina, M., (2015) World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends, Alzheimer's Disease International (ADI), London
dc.creator.googleOrtiz-Guerrero, G., Amador-Muñoz, D., Calderón-Ospina, C.A., López-Fuentes, D., Mesa, M.O.N.
dc.identifier.doi10.1155/2018/5257285


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

 

Reconocimientos: